WEBULL

McKesson (MCK): Assessing Valuation Following Recent Share Price Movement

Simply Wall St · 08/22/2025 10:26

McKesson (MCK) turned some heads this week after a small climb in its share price drew fresh attention from investors weighing their next move. While there was no headline-grabbing event to explain the latest uptick, subtle shifts often leave market-watchers curious: are these signals of changing sentiment or simply noise in the short run? With McKesson’s footprint spanning pharmaceutical distribution and healthcare services, even incremental moves can hint at evolving dynamics beneath the surface.

Taking a step back, this comes after a steady run for McKesson, with the stock posting a 26% gain over the past year and an impressive three-year return close to 95%. The momentum has cooled a bit in the past month, with a slight dip, but the longer view still suggests meaningful growth. Recently, the company posted moderate annual revenue and net income growth, adding context for those questioning if its long-term rally has run its course or if this is merely a pause.

With this backdrop, the question for investors is clear: is McKesson’s current price leaving upside on the table, or is the market already factoring in any future gains?

Most Popular Narrative: 10.5% Undervalued

According to community narrative, McKesson is currently undervalued by a notable margin compared to its assessed fair value. This perspective grounds its valuation in robust forecasts for revenue and earnings growth, relying on anticipated operational improvements and market shifts.

"Investments in digitization, automation, and advanced analytics across distribution centers and logistics (such as automated picking systems, AI, and robotics) are enhancing operational efficiency. These investments are driving measurable reductions in operating expenses and supporting long-term net margin improvement. Expanding value-added services, such as pharmacy management, patient access and adherence solutions, and commercialization support for biopharma customers, allow for stronger customer relationships, greater recurring revenue streams, and improved revenue visibility."

Curious about how analysts determine fair value for one of healthcare’s biggest distributors? The secret mix of efficiency improvements, new recurring revenue streams, and transformations in specialty pharmaceuticals could set the stage for a re-rating. What are the assumptions that really drive this undervaluation call? The math behind the analysts’ target may surprise you.

Result: Fair Value of $788.57 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing regulatory scrutiny of drug pricing and consolidation among healthcare players could still challenge McKesson’s long-term growth story.

Find out about the key risks to this McKesson narrative.

Another View: Market Ratios Paint a Different Picture

Taking a closer look at traditional price-based ratios tells a different story. Compared to others in its sector, McKesson’s current pricing appears more expensive. Does this challenge the growth narrative or suggest that there is justified optimism?

See what the numbers say about this price — find out in our valuation breakdown.
NYSE:MCK PE Ratio as at Aug 2025
NYSE:MCK PE Ratio as at Aug 2025
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out McKesson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own McKesson Narrative

If you’d like to draw your own conclusions or take another angle on McKesson’s outlook, you can easily map out your perspective. Just set aside a few minutes and do it your way.

A great starting point for your McKesson research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Don’t wait for the next headline to shape your portfolio. Expand your search with some of the stock market’s most intriguing opportunities, tailored to meet different interests and strategies. You’ll want to check these out before the market catches on:

  • Capitalize on tech’s hottest trend by uncovering the most promising AI penny stocks. Here, artificial intelligence innovation meets real business growth.
  • Boost your income potential and tap into reliable returns with a lineup of companies offering strong dividend stocks with yields > 3% for steady cash flow.
  • Position yourself at the forefront of finance by selecting from standout cryptocurrency and blockchain stocks. These are reshaping industries with blockchain and digital assets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.